Certain Dermatological Treatment Devices and Components Thereof II; Inv. No. 337-TA-1515 (Violation)

This supplemental complaint, filed by Serendia, LLC in Inv. No. 337-TA-1515, supplements the original complaint by replacing the respondent-description paragraphs for InMode and BTL entities, restating the accused product category as RF microneedling dermatological treatment devices, updating the related litigation paragraph, and adding importation evidence and new exhibits. The supplement strengthens the allegations that the named InMode and BTL entities import and sell RF microneedling devices in the United States, which supports the unfair import allegations that underlie any exclusion order. The text does not identify the asserted patents or the relief requested, and it does not state the relief sought. Complainant Serendia, LLC, through Latham & Watkins, supplements its complaint by letter to the Commission Secretary dated July 6, 2026. Respondent paragraphs are replaced for InMode Ltd., Invasix Inc., BTL Industries, Inc., BTL Industries Limited, BTL Industries JSC, BTL Healthcare Technologies A/S, BTL Enterprise Group A/S, BTL Medical Technologies S.R.O., and BTL Holding Limited. Accused product category is restated under 19 C.F.R. 210.12(a)(12) as RF microneedling dermatological treatment devices and components, including consoles, handpieces, and needle tips. Related litigation is described as civil actions in the Central District of California against InMode and in the District of Massachusetts against BTL. New paragraphs 7.5.1 and 7.10 allege continued importation and sale of the InMode Accused Products (Morpheus8) and the BTL Accused Products (Exion), citing provider advertisements. Exhibits 10, 24 and 26 are replaced and new Exhibits 48 through 66 are added.